On Tuesday, a committee that advises the Food and Drug Administration is to consider whether the first of those drugs can overcome safety concerns and reach the market.

The outcome of the F.D.A. review is far from certain. The drug, dapagliflozin, might raise the risk of breast and bladder cancer, liver damage and infections of the genitals and urinary tract, according to an F.D.A.